Screening and identification of candidate therapeutic drugs from plants for the management of patients infected bacterial infection associated with SARS COV-2

The emergence of COVID-19 (SARS-COV-2) has resulted in millions of deaths worldwide. Nigeria has recorded over 2000 deaths due to the disease. Development of alternative medicine from plants against SARS-COV-2 can be a potential therapy for treatment of secondary complications. To investigate plants with potential to manage respiratory tract infections. The plants were extracted and screened for phytochemical constituents; their acute and subacute toxicity profile was evaluated. The plant extracts were tested against clinical microbial isolates associated with respiratory tract infection. All the plants extract were found to have acute toxicity dose above 5000 mg per kg body weight. Among the four tested medicinal plants Guiera senegalensis was found to have significant zone of inhibition against Klebsiella pneumonia and Moraxella catarrhalis more than the standard drug (Gentamicin). Guiera senegalensis has been used in traditional medicine to treat bacterial infections without any report of toxicity. The preclinical study indicated that Guiera senegalensis can be used in the management of respiratory infections associated with symptoms of COVID 19. Guiera senegalensis can therefore be used as a potential medicinal plant for management of secondary bacterial infections in Covid19 patients.